Alzamend Neuro, Inc. (ALZN)Healthcare | Biotechnology | Atlanta, United States | NasdaqCM
1.11 USD
-0.01
(-0.893%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:30 a.m. EDT
ALZN presents a bearish short-term outlook with a high-conviction sell signal driven by a strong negative forecast (-10.5% downside), multi-month price breakdowns below psychological support levels, and neutralization of long-term bullish analyst sentiment by deteriorating equity structure (Nasdaq deficiency notice). |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.277416 |
| MSTL | 0.291817 |
| AutoETS | 0.292681 |
| AutoARIMA | 0.312152 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 26.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.019 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,223,262 |
| Forward P/E | -0.43 |
| Beta | -0.05 |
| Website | https://www.alzamend.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.82125604 |
| Address1 | 3,480 Peachtree Road NE |
| Address2 | Second Floor, Suite 103 |
| All Time High | 45,292.5 |
| All Time Low | 0.84 |
| Ask | 1.17 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 100,080 |
| Average Daily Volume3 Month | 149,570 |
| Average Volume | 149,570 |
| Average Volume10Days | 100,080 |
| Beta | -0.051 |
| Bid | 1.07 |
| Bid Size | 1 |
| Book Value | 0.574 |
| City | Atlanta |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.11 |
| Current Ratio | 1.992 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.13 |
| Day Low | 1.0576 |
| Display Name | Alzamend Neuro |
| Earnings Timestamp End | 1,754,164,800 |
| Earnings Timestamp Start | 1,753,732,800 |
| Ebitda | -6,939,160 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.218 |
| Enterprise Value | 1,510,123 |
| Eps Current Year | -2.58 |
| Eps Forward | -2.6 |
| Eps Trailing Twelve Months | -3.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.63436 |
| Fifty Day Average Change | -0.52435994 |
| Fifty Day Average Change Percent | -0.32083505 |
| Fifty Two Week Change Percent | -82.1256 |
| Fifty Two Week High | 8.22 |
| Fifty Two Week High Change | -7.11 |
| Fifty Two Week High Change Percent | -0.8649635 |
| Fifty Two Week Low | 0.84 |
| Fifty Two Week Low Change | 0.27000004 |
| Fifty Two Week Low Change Percent | 0.32142863 |
| Fifty Two Week Range | 0.84 - 8.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,763,800,000 |
| Float Shares | 3,792,870 |
| Forward Eps | -2.6 |
| Forward P E | -0.4269231 |
| Free Cashflow | -3,615,899 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0053 |
| Held Percent Institutions | 0.064559996 |
| Implied Shares Outstanding | 3,804,741 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,745,971,200 |
| Last Split Date | 1,747,008,000 |
| Last Split Factor | 1:9 |
| Long Business Summary | Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. |
| Long Name | Alzamend Neuro, Inc. |
| Market | us_market |
| Market Cap | 4,223,262 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_367712111 |
| Most Recent Quarter | 1,769,817,600 |
| Net Income To Common | -7,544,730 |
| Next Fiscal Year End | 1,777,507,200 |
| Non Diluted Market Cap | 4,223,262 |
| Number Of Analyst Opinions | 1 |
| Open | 1.08 |
| Operating Cashflow | -5,959,224 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 844 722 6333 |
| Pre Market Change | -0.00999999 |
| Pre Market Change Percent | -0.9009 |
| Pre Market Price | 1.1 |
| Pre Market Time | 1,776,775,011 |
| Previous Close | 1.12 |
| Price Eps Current Year | -0.43023258 |
| Price Hint | 4 |
| Price To Book | 1.933798 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.461 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.01 |
| Regular Market Change Percent | -0.892856 |
| Regular Market Day High | 1.13 |
| Regular Market Day Low | 1.0576 |
| Regular Market Day Range | 1.0576 - 1.13 |
| Regular Market Open | 1.08 |
| Regular Market Previous Close | 1.12 |
| Regular Market Price | 1.11 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 22,058 |
| Return On Assets | -1.07011 |
| Return On Equity | -2.49965 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,804,741 |
| Shares Percent Shares Out | 0.0857 |
| Shares Short | 326,187 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 269,773 |
| Short Name | Alzamend Neuro, Inc. |
| Short Percent Of Float | 0.0862 |
| Short Ratio | 1.33 |
| Source Interval | 15 |
| State | GA |
| Symbol | ALZN |
| Target High Price | 25.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 25.0 |
| Total Cash | 2,713,139 |
| Total Cash Per Share | 0.713 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.20008 |
| Two Hundred Day Average Change | -1.0900799 |
| Two Hundred Day Average Change Percent | -0.49547288 |
| Type Disp | Equity |
| Volume | 22,058 |
| Website | https://www.alzamend.com |
| Zip | 30,326 |